Abivax SA ADS/$ABVX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Abivax SA ADS
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.
Ticker
$ABVX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
69
ISIN
US00370M1036
Website
Abivax SA ADS Metrics
BasicAdvanced
$466M
-
-$3.45
-
-
Price and volume
Market cap
$466M
52-week high
$8.61
52-week low
$4.77
Average daily volume
268K
Financial strength
Current ratio
1.255
Quick ratio
1.157
Long term debt to equity
-943.538
Total debt to equity
-1,616.535
Interest coverage (TTM)
-12.07%
Profitability
EBITDA (TTM)
-204.416
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-1,754.30%
Operating margin (TTM)
-1,657.65%
Revenue per employee (TTM)
$175,820
Management effectiveness
Return on equity (TTM)
-196.12%
Valuation
Price to revenue (TTM)
37.661
Price to book
-60.22
Price to tangible book (TTM)
-12.56
Price to free cash flow (TTM)
-2.602
Free cash flow yield (TTM)
-38.44%
Free cash flow per share (TTM)
-284.44%
Growth
Revenue change (TTM)
128.98%
Earnings per share change (TTM)
-11.01%
3-year revenue growth (CAGR)
111.82%
10-year revenue growth (CAGR)
40.87%
3-year earnings per share growth (CAGR)
3.28%
10-year earnings per share growth (CAGR)
13.00%
Bulls say / Bears say
Abivax has completed enrollment for its Phase 3 ABTECT trials evaluating obefazimod for moderately to severely active ulcerative colitis, with top-line results expected in Q3 2025, potentially leading to significant market opportunities if successful. (GlobeNewswire)
The company maintains a strong cash position of EUR 144.2 million as of December 31, 2024, providing a projected financial runway into Q4 2025, supporting ongoing clinical developments without immediate need for additional financing. (Abivax)
Analysts have a consensus 'Strong Buy' rating for Abivax, with an average 12-month price target of $32.50, indicating significant upside potential from the current stock price. (TipRanks)
Abivax reported an increased operating loss of EUR 42.7 million in the first half of 2024, reflecting higher R&D expenses and raising concerns about financial sustainability if losses continue. (TipRanks)
The company's At-The-Market (ATM) program allows for the issuance of up to $150 million in new shares, potentially leading to shareholder dilution of approximately 39.5% if fully utilized. (Nasdaq)
Morgan Stanley has reiterated an 'Equal Weight' rating for Abivax with a price target of $12.00, suggesting limited upside potential compared to more optimistic analyst forecasts. (MarketBeat)
Data summarised monthly by Lightyear AI. Last updated on 4 Jun 2025.
Abivax SA ADS News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Abivax SA ADS stock?
Abivax SA ADS (ABVX) has a market cap of $466M as of June 30, 2025.
What is the P/E ratio for Abivax SA ADS stock?
The price to earnings (P/E) ratio for Abivax SA ADS (ABVX) stock is 0 as of June 30, 2025.
Does Abivax SA ADS stock pay dividends?
No, Abivax SA ADS (ABVX) stock does not pay dividends to its shareholders as of June 30, 2025.
When is the next Abivax SA ADS dividend payment date?
Abivax SA ADS (ABVX) stock does not pay dividends to its shareholders.
What is the beta indicator for Abivax SA ADS?
Abivax SA ADS (ABVX) does not currently have a Beta indicator.